864 related articles for article (PubMed ID: 26836711)
21. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
22. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
23. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
24. Study on the Pulmonary Delivery System of Apigenin-Loaded Albumin Nanocarriers with Antioxidant Activity.
Pápay ZE; Kósa A; Böddi B; Merchant Z; Saleem IY; Zariwala MG; Klebovich I; Somavarapu S; Antal I
J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):274-288. PubMed ID: 28282259
[TBL] [Abstract][Full Text] [Related]
25. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Particle Size and Surface Roughness of Spray-Dried Bosentan Microparticles on Aerodynamic Performance for Dry Powder Inhalation.
Kwon YB; Kang JH; Han CS; Kim DW; Park CW
Pharmaceutics; 2020 Aug; 12(8):. PubMed ID: 32823545
[TBL] [Abstract][Full Text] [Related]
27. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
28. Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols.
Lee HJ; Kang JH; Lee HG; Kim DW; Rhee YS; Kim JY; Park ES; Park CW
Drug Des Devel Ther; 2016; 10():4017-4030. PubMed ID: 28008226
[TBL] [Abstract][Full Text] [Related]
29. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
30. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
31. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
32. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
Corrigan DO; Corrigan OI; Healy AM
Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
[TBL] [Abstract][Full Text] [Related]
33. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation.
Schoubben A; Vivani R; Paolantoni M; Perinelli DR; Gioiello A; Macchiarulo A; Ricci M
Eur J Pharm Sci; 2019 Mar; 130():54-64. PubMed ID: 30677523
[TBL] [Abstract][Full Text] [Related]
34. Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery.
Li X; Mansour HM
AAPS PharmSciTech; 2011 Dec; 12(4):1420-30. PubMed ID: 22038473
[TBL] [Abstract][Full Text] [Related]
35. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
36. Impact of dispersion media and carrier type on spray-dried proliposome powder formulations loaded with beclomethasone dipropionate for their pulmonary drug delivery via a next generation impactor.
Khan I; Al-Hasani A; Khan MH; Khan AN; -Alam FE; Sadozai SK; Elhissi A; Khan J; Yousaf S
PLoS One; 2023; 18(3):e0281860. PubMed ID: 36913325
[TBL] [Abstract][Full Text] [Related]
37. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
Akdag Cayli Y; Sahin S; Buttini F; Balducci AG; Montanari S; Vural I; Oner L
Drug Dev Ind Pharm; 2017 Aug; 43(8):1378-1389. PubMed ID: 28420285
[TBL] [Abstract][Full Text] [Related]
38. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
39. Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.
Mangal S; Nie H; Xu R; Guo R; Cavallaro A; Zemlyanov D; Zhou QT
Pharm Res; 2018 Jan; 35(2):28. PubMed ID: 29374368
[TBL] [Abstract][Full Text] [Related]
40. Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system.
Alhajj N; O'Reilly NJ; Cathcart H
Int J Pharm; 2022 Apr; 618():121657. PubMed ID: 35288220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
